- Home
- AVIR vs BGY Comparison
AVIR vs BGY Comparison
Compare AVIR & BGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVIR | BGY |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.5M | 515.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVIR | BGY |
|---|---|---|
| Price | $4.19 | $5.64 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 286.4K | ★ 309.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.41% |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $5.19 |
| 52 Week High | $6.45 | $6.23 |
Technical Indicators
Market Signals| Indicator | AVIR | BGY |
|---|---|---|
| Relative Strength Index (RSI) | 25.08 | 44.27 |
| Support Level | $3.32 | $5.49 |
| Resistance Level | $4.34 | $5.87 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 6.70 | 23.21 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About BGY Blackrock Enhanced International Dividend Trust
Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.